A clinical study of mycophenolate mofetil combined with low-dose steroids in the management of pediatric systemic lupus erythematosus

Purpose: To investigate the efficacy and safety of mycophenolate mofetil (MMF) combined with lowdose steroids in treatment pediatric systemic lupus erythematosus (pSLE).Methods: A total 76 children were diagnosed admitted SLE, nephritis (LN) type IV diffuse proliferative glomerulonephritis at Hainan Women Children’s Medical Center, Haikou, China from March 2017 to December 2018, had their clinical data analyzed retrospectively. Among them, 38 received methylprednisolone pulse MMF intermittent oral low-dose glucocorticoids (GC), labelled group, while remaining children, which served as control treated GC transitional reduction. Pertinent biochemical parameters evaluatedResults: Compared group showed a notably lower level erythrocyte sedimentation rate (ESR), higher complement C3, serum creatinine (Scr) 24-h urine protein 6 months after (p < 0.05). Albumin was 12 than group. SLEDAI score significantly Body mass index, triglyceride, fasting blood glucose intraocular pressure levels those Post-treatment, peripheral CD3+ CD4+ T lymphocytes, CD4+/CD8+ ratio NK cell two groups increased, CD8+ lymphocyte declined.Conclusion: controls symptoms early mitigates renal injury pSLE. It is also safe, effectively regulates patient's cellular immune function.